NTV Asset Management LLC Sells 4,197 Shares of Abbott Laboratories (NYSE:ABT)

NTV Asset Management LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 10.6% in the 4th quarter, Holdings Channel reports. The firm owned 35,370 shares of the healthcare product maker’s stock after selling 4,197 shares during the quarter. NTV Asset Management LLC’s holdings in Abbott Laboratories were worth $3,893,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Abbott Laboratories by 4.3% in the third quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock valued at $3,022,564,000 after buying an additional 1,298,219 shares during the period. Northern Trust Corp boosted its position in shares of Abbott Laboratories by 1.5% during the 3rd quarter. Northern Trust Corp now owns 23,016,235 shares of the healthcare product maker’s stock valued at $2,229,122,000 after purchasing an additional 343,559 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Abbott Laboratories by 0.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 12,153,877 shares of the healthcare product maker’s stock worth $1,164,611,000 after purchasing an additional 32,157 shares during the period. Fisher Asset Management LLC increased its holdings in Abbott Laboratories by 2.4% in the fourth quarter. Fisher Asset Management LLC now owns 9,930,872 shares of the healthcare product maker’s stock worth $1,093,091,000 after purchasing an additional 236,741 shares in the last quarter. Finally, Flossbach Von Storch AG boosted its holdings in shares of Abbott Laboratories by 1.5% during the 4th quarter. Flossbach Von Storch AG now owns 9,149,611 shares of the healthcare product maker’s stock worth $1,007,098,000 after buying an additional 135,821 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the sale, the executive vice president now owns 125,697 shares in the company, valued at $14,895,094.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the sale, the vice president now owns 18,760 shares in the company, valued at $2,223,060. The disclosure for this sale can be found here. Insiders sold 13,935 shares of company stock worth $1,670,048 in the last quarter. 1.10% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Down 0.0 %

ABT traded down $0.02 during mid-day trading on Friday, reaching $105.90. 3,610,492 shares of the stock were exchanged, compared to its average volume of 5,320,693. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64. The stock has a market capitalization of $183.76 billion, a PE ratio of 32.99, a price-to-earnings-growth ratio of 2.55 and a beta of 0.76. The company has a 50 day moving average price of $112.52 and a two-hundred day moving average price of $108.51.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The business had revenue of $9.96 billion for the quarter, compared to analysts’ expectations of $9.88 billion. During the same period in the previous year, the company earned $1.03 earnings per share. The firm’s revenue for the quarter was up 2.2% compared to the same quarter last year. As a group, research analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be given a $0.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 2.08%. Abbott Laboratories’s dividend payout ratio is currently 68.54%.

Analyst Ratings Changes

ABT has been the topic of a number of research reports. Raymond James reiterated a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Citigroup increased their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Barclays decreased their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, April 22nd. Evercore ISI increased their price target on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Royal Bank of Canada decreased their price objective on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, April 18th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $121.50.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.